Anticorps Recombinant de lapin anti-SLC7A11/xCT
SLC7A11/xCT Recombinant Antibody for IF/ICC, FC (Intra), Indirect ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain
Applications
IF/ICC, FC (Intra), Indirect ELISA
Conjugaison
Non conjugué
CloneNo.
230227C5
N° de cat : 82115-2-PBS
Synonymes
Galerie de données de validation
Informations sur le produit
82115-2-PBS cible SLC7A11/xCT dans les applications de IF/ICC, FC (Intra), Indirect ELISA et montre une réactivité avec des échantillons Humain
| Réactivité | Humain |
| Hôte / Isotype | Lapin / IgG |
| Clonalité | Recombinant |
| Type | Anticorps |
| Immunogène | SLC7A11/xCT Protéine recombinante Ag25431 |
| Nom complet | solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 |
| Masse moléculaire calculée | 55 kDa |
| Numéro d’acquisition GenBank | BC012087 |
| Symbole du gène | SLC7A11 |
| Identification du gène (NCBI) | 23657 |
| Conjugaison | Non conjugué |
| Forme | Liquide |
| Méthode de purification | Purification par protéine A |
| Tampon de stockage | PBS only |
| Conditions de stockage | Store at -80°C. 20ul contiennent 0,1% de BSA. |
Informations générales
SLC7A11 (also known as xCT) is a membrane transporter involved in the uptake of cystine. It promotes glutathione synthesis through the uptake of cystine and the concomitant release of glutamate. This, in turn, protects cells from oxidative stress, maintains cellular redox balance, and prevents cell death induced by lipid peroxidation. SLC7A11 has been identified as a potential target for cancer therapeutics. It is overexpressed in multiple malignant tumors and is closely associated with the growth, prognosis, metastasis, and treatment response of various cancers including lung cancer.







